Nina Krajcar

Dr. Nina Krajcar

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Croatian Medical Journal
Verified
Journal Article
Open access
NKNina Krajcar
Nina Krajcar
LMLorna Stemberger Marić
Lorna Stemberger Marić
AŠAnja Šurina
Anja Šurina
SFSanja Kurečić Filipović
Sanja Kurečić Filipović
VTVladimir Trkulja
Vladimir Trkulja
GTGoran Tešović
Goran Tešović
Data on patients aged ≤19 years with a positive SARS-CoV-2 PCR test recorded in the period March 12-May 12 (first wave) and June 19-July 19, 2020 (second wave) were retrospectively analyzed. The periods were separated by several weeks with no ...

7 February 2025 in Vaccine
Verified
Journal Article
Open access
NKNina Krajcar
Nina Krajcar
VTVladimir Trkulja
Vladimir Trkulja
IBIva Butić
Iva Butić
GTGoran Tešović
Goran Tešović
In 2019, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in the Croatian immunization programme, a first for this European PCV-naïve country. This study aimed to evaluate the impact of PCV10 on pneumococcal serotype distribution among asymptomatic children and children with pneumonia and/or acute otitis media. Cross-sectional studies were conducted before and after the PCV10 introduction, with nasopharyngeal swabs collected from 1500 healthy children under 48 months of age. An additional 324 children under 18 years with pneumonia and/or acute otitis media, from whom Streptococcus pneumoniae was isolated, were also included. Isolates were identified by conventional methods, serotyped by Quellung reaction, and tested for antimicrobial susceptibility using disk diffusion and gradient test methods. We report prevalence, absolute risk (prevalence) difference (RD) and relative risk (prevalence) ratio (RR) differences between exposed and control children. Carriage prevalence among healthy children increased from 19.9% to 28.7%, primarily due to a rise in non-vaccine serotypes (NVT). Adjusted probabilities for serotypes 6C (RR 3.18; 95% CI, 1.43-7.06), 11A (RR 2.8; 95% CI, 1.22-6.39), 19A (RR 4.18; 95% CI, 1.18-14.9) and 23A (RR 3.93; 95% CI, 1.87-8.24) were significantly higher in healthy exposed children. Prevalences of these serotypes were also higher in exposed children with pneumonia/acute otitis media. In this cohort, serotype 3 increased (RR 4.6; 95% CI, 2.02-10.3), becoming the leading post-PCV10 isolate in the overall studied population. Serotypes 3 and 19A were almost entirely responsible for complicated pneumonia cases for which the probability increased by 21-fold. Antimicrobial susceptibility remained similar across periods. In the early post-vaccine period significant increase of PCV10 vaccine-related serotypes (6C, 19A) was observed. Continued monitoring is also essential due to concerning rise of serotype 3 in patients with mucosal infections and a higher risk for complicated pneumonia.

22 April 2019 in Journal of Chemotherapy
Verified
Journal Article
Closed access
NKNina Krajcar
Nina Krajcar
LMLorna Stemberger Marić
Lorna Stemberger Marić
DŠDalibor Šarić
Dalibor Šarić
NMNeven Milić
Neven Milić
GTGoran Tešović
Goran Tešović
Infective endocarditis (IE) is uncommon in children, affecting predominantly subjects with congenital heart disease (CHD) and patients with indwelling central lines. The principles of antibiotic treatment in paediatric population are similar to those in adults. Prolonged intravenous administration of bactericidal rather than bacteriostatic agents is preferred. Outpatient intravenous therapy after initial treatment in the hospital may be considered only in selected patients. Partial oral treatment has been described in cases of left-sided, uncomplicated IE caused by common pathogens in adult patients. There are no guidelines or trials in paediatric population regarding switching therapy from intravenous to oral route. We present two cases of IE in children caused by uncommon pathogenic bacteria (Abiotrophia defectiva and Haemophilus parainfluenzae) successfully treated with oral third-generation cephalosporin - cefpodoxime proxetil after initial intravenous therapy. This paper provides observations on different therapeutic approach for IE in children as well as another potential use of cefpodoxime proxetil.

7 June 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
NKNina Krajcar
Nina Krajcar
LMLorna Stemberger Marić
Lorna Stemberger Marić
SRSrđan Roglić
Srđan Roglić
GTGoran Tesovic
Goran Tesovic

20 August 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
IVIvana Valenčak
Ivana Valenčak
NKNina Krajcar
Nina Krajcar
DDDiana Didović
Diana Didović
SRSrđan Roglić
Srđan Roglić
IBIva Butic
Iva Butic
GTGoran Tesovic
Goran Tesovic
Background: Campylobacter jejuni is a common cause of acute gastroenteritis, but central nervous system infections are rare manifestations of Campylobacter infection. Therefore, C. jejuni trauma-related subdural hygroma infection in children is poorly described in the literature. Case presentation: We described a 2-year old boy with lobar holoprosencephaly presenting with subdural hygroma following head trauma. C. jejuni infection was confirmed from a subdural hygroma sample by culture as well as by DNA sequencing of a broad range 16S rDNA PCR product. Cerebrospinal fluid from the ventriculoperitoneal shunt remained sterile. Combined neurosurgical and antimicrobial treatment led to complete recovery. Review of the literature showed that the most common manifestation of Campylobacter central nervous system infection is meningitis, mostly in neonates, and subdural hygroma infection was described for only one case. Conclusions: Subdural hygroma infection caused by C. jejuni is a rare clinical condition in children. Molecular methods represent an important tool for the detection of rare or unexpected pathogens. No standard recommendations for antimicrobial treatment of C. jejuni subdural space infection in children are available, but meropenem treatment combined with surgery seems to be an effective approach.

5 September 2024 in Eurosurveillance
Verified
Journal Article
Open access
TBTatjana Nemeth Blažić
Tatjana Nemeth Blažić
NKNina Krajcar
Nina Krajcar
MLMirjana Lana Kosanović Ličina
Mirjana Lana Kosanović Ličina
DLDominik Ljubas
Dominik Ljubas
OMOtilia Mardh
Otilia Mardh
IBIvana Božičević
Ivana Božičević
Four infants potentially exposed to syphilis infection in utero, meeting World Health Organization surveillance criteria of congenital syphilis (CS), were diagnosed in Croatia between September 2020 and January 2024. We conducted a retrospective analysis of epidemiological, clinical and laboratory data of these cases to assess compliance with surveillance case definitions. As only one confirmed CS case has been reported in Croatia in over 2 decades, these reports signal an increased risk of syphilis vertical transmission and warrant strengthening antenatal screening.